3O'Hagan DT, Mackichan ML, Singh M. Recent developments in adjuvants for vaccines against infectious diseases.Biomol Eng 2001; 18: 69-85.
4Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19: 2666-72.
5Kensil Cr, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillja saponaria Molina cortex. J Immunol 1991: 146: 431-7.
6Nord LI, Kenne L. Separation and structural analysis of saponins in a bark extract from Quillja saponaria Molina.Carbohydr Res 1999; 320: 70-81.
7Newman MJ, Wu YY, Gardner BH, Anderson CA, Kensil CR, Recchia J, et al. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gpl20 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. Vaccine 1997; 15: 1001-7.
8Waite DC, Jacobson EW, Ennis FA, Edelman R, White B,Kammer R, et al. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. Vaccine 2001; 19: 3957-67.
9Marciani DJ, Press JB, Reynolds RC, Pathak AK, Pathak V,Gundy LE, et al. Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity. Vaccine 2000; 18: 3141-51.
10Marciani DJ, Pathak AK, Reynolds RC, Seitz L, May RD.Altered immunomodulating and toxicological properties of degraded Quillajia saponaria Molina saponins. Int Immunopharmacol 2001; 1: 813-8.
